Drug Profile
Research programme: meloxicam depot - Encore Therapeutics
Alternative Names: ETI-511Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Encore Therapeutics
- Class 2 ring heterocyclic compounds; Amides; Analgesics; Anti-inflammatories; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Thiazines; Thiazoles
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Arthritis; Postoperative inflammation; Postoperative pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Arthritis in USA (SC, Controlled release)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Postoperative-inflammation in USA (SC, Controlled release)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Postoperative-pain in USA (SC, Controlled release)